27 August 2021 - A unique partnership between Pharmascience and the Montreal Heart Institute leads to the approval of Myinfla (colchicine 0.5 mg extended release tablets), a known drug repurposed as a new treatment option for the reduction of cardiovascular risks in patients with coronary artery disease.

Pendopharm is pleased to announce that Health Canada has issued a Notice of Compliance approving Myinfla (colchicine 0.5 mg extended release tablets), a prescription medicine for use in the reduction of cardiovascular risks in patients with coronary artery disease. 

Read Pendopharm press release